<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615546</url>
  </required_header>
  <id_info>
    <org_study_id>52254</org_study_id>
    <nct_id>NCT04615546</nct_id>
  </id_info>
  <brief_title>Role of Nutrient Transit in Hyperinsulinemic Hypoglycemia</brief_title>
  <official_title>Role of Nutrient Transit and Incretin Hormones in Hyperinsulinemic Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe hypoglycemia (low blood sugar)after gastric bypass surgery is an increasingly&#xD;
      recognized condition, characterized by symptoms of hypoglycemia after eating and&#xD;
      inappropriately elevated insulin concentrations that occur at the time of hypoglycemia.&#xD;
      Severe hypoglycemia can be dangerous and debilitating and can also impact cognitive function.&#xD;
      At the moment no medical therapies have been developed for this disorder. Determining why&#xD;
      some but not other patients develop this condition would allow for improved prediction,&#xD;
      prevention, and treatment approaches. The purpose of the study is to understand the&#xD;
      physiological changes observed in those patients who undergo gastric bypass and develop&#xD;
      symptomatic hypoglycemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady state plasma glucose as a measure of insulin sensitivity</measure>
    <time_frame>Measurement on a single study visit (1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of gastric emptying</measure>
    <time_frame>Measurement on a single study visit (1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GLP-1 secretion augmentation of insulin secretion rate</measure>
    <time_frame>Measurement on a single study visit (1 day)</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post-Bariatric Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Remote Phase: PBH Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will wear continuous glucose monitor (CGM) in a blinded manner (cannot see data output) for 20 days followed by in an unblinded manner (can see data output) for 20 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Clinic Phase: PBH Patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions. This group will also wear CGM during a portion of the metabolic tests. May include participants from the Remote Phase or newly enrolled participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Clinic Phase: Surgical Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Clinic Phase: Nonsurgical Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Clinic Phase: PBH Patients with indwelling gastrostomy tube</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will undergo standardized mixed meal tolerance tests via oral, gastrostomy tube, and concomitant oral + gastrostomy tube routes of delivery with metabolic parameters assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Use of Continuous Glucose Monitor (CGM)</intervention_name>
    <description>Participants will wear CGM</description>
    <arm_group_label>Remote Phase: PBH Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Use of Cardea Solo monitoring</intervention_name>
    <description>Participants will wear a Cardea Solo patch during blinded CGM use</description>
    <arm_group_label>Remote Phase: PBH Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients 18-70 years of age&#xD;
&#xD;
          -  Post-bariatric surgery more than 6 months prior to signing the informed consent (not&#xD;
             required for non-surgical controls)&#xD;
&#xD;
          -  Documented history of hyperinsulinemic hypoglycemia (not required for post-bariatric&#xD;
             and non-surgical controls)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients currently using sulfonylureas or other medications that may interfere with&#xD;
             glucose metabolism within 5 half-lives of drug.&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 weeks prior to dosing&#xD;
&#xD;
          -  History of or current insulinoma&#xD;
&#xD;
          -  Active infection or significant acute illness within 2 weeks prior to dosing&#xD;
&#xD;
          -  Female patients who are pregnant or lactating&#xD;
&#xD;
          -  Women of childbearing potential and not utilizing effective contraceptive methods&#xD;
&#xD;
          -  Inadequate end organ function as defined by: Serum creatinine &gt;2.0 mg/dL, ALT and AST&#xD;
             &gt; 2 x UNL&#xD;
&#xD;
          -  Allergy to test meal or medications used in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracey McLaughlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Craig, MD</last_name>
      <phone>650-724-2474</phone>
      <email>cmcraig@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Colleen Craig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Tracey McLaughlin</investigator_full_name>
    <investigator_title>Professor of Medicine, Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

